Changes in Hong Kong stocks | Pharmaceuticals Juno-B (02126) rose more than 5% to transfer rights in the liver cancer TCR-T program to Eurico Hong Kong

The Zhitong Finance App learned that Pharmaceutical Junuo B (02126) rose by more than 5%. As of press release, it had risen 4.67% to HK$2.69, with a turnover of HK$1,269,200.

According to the news, Pharmaceutical Juno-B announced that the JW contracting party (Company and JWS) signed a license and transfer agreement with Eureka Contractor (Eureka Cayman) and Eureka Cayman) and Eureka Hong Kong on November 9, 2026 (after the trading period). Based on this, JWS transferred all of its rights, title and interest in the transferred assets (including Eureko licenses) to Eureko Hong Kong, and each JW contracting party granted an exclusive charging license to use Eureko Hong Kong's licensed assets in exchange for the use of products in the regional field The total cost.

As part of the price of the transfer of assets by JWS and the licensing of the licensed assets by the JW Contractor, Eureko Hong Kong (or Eureko's Hong Kong affiliate designated in writing) must pay the JW Contractor a non-refundable, non-deductible and irrevocable one-time advance payment of $10 million on or before the effective date. Assuming that Eureko Group enters into a transaction within the qualifying period and that Eureko Group achieves all three net sales targets within the milestone period, the total amount of commercial milestone payments will not exceed $100 million.